Provided by Tiger Trade Technology Pte. Ltd.

Incyte

94.22
+1.221.31%
Post-market: 94.270.0502+0.05%17:18 EDT
Volume:1.86M
Turnover:175.75M
Market Cap:18.75B
PE:14.70
High:94.91
Open:93.04
Low:93.04
Close:93.00
52wk High:112.29
52wk Low:53.56
Shares:199.01M
Float Shares:163.04M
Volume Ratio:1.09
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.41
EPS(LYR):6.41
ROE:29.87%
ROA:13.57%
PB:3.63
PE(LYR):14.70

Loading ...

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
4 hours ago

BRIEF-Knight Therapeutics Announces Approval Of Additional Indication For Minjuvi® (Tafasitamab) In Brazil

Reuters
·
Yesterday

Knight Therapeutics Announces Approval of Additional Indication for Minjuvi® (Tafasitamab) in Brazil

THOMSON REUTERS
·
Yesterday

Knight Therapeutics Announces Regulatory Supplemental Submission of Minjuvi® (Tafasitamab) for Follicular Lymphoma in Argentina and Mexico

THOMSON REUTERS
·
Yesterday

Incyte Cut to Hold From Buy by Jefferies

Dow Jones
·
Mar 16

U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics

Reuters
·
Mar 16

Incyte Corp. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Mar 13

Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Mar 11

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Mar 10

Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Incyte (INCY)

TIPRANKS
·
Mar 09

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF), Incyte (INCY) and Oncology Institute (TOI)

TIPRANKS
·
Mar 09

Incyte Price Target Maintained With a $135.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 09

Incyte Says FDA Declines Supplemental Biologics Application for Zynyz Injection

MT Newswires Live
·
Mar 09

Balancing Post‑Jakafi Opportunities and Execution Risks: Rationale Behind a Neutral Stance on Incyte

TIPRANKS
·
Mar 07

Incyte Faces FDA Setback on Zynyz Lung Cancer Expansion

TIPRANKS
·
Mar 07

BRIEF-Incyte - FDA Issues Complete Response Letter For Zynyz Sbla In Nsclc - SEC Filing

Reuters
·
Mar 07

Incyte - FDA Issues Complete Response Letter for Zynyz Sbla in Nsclc - SEC Filing

THOMSON REUTERS
·
Mar 07

Incyte - Crl Cites Catalent Indiana Regulatory Compliance as Sole Approvability Issue - SEC Filing

THOMSON REUTERS
·
Mar 07

FDA issues Complete Response Letter for Incyte’s Zynyz NSCLC sBLA over Catalent Indiana compliance findings

Reuters
·
Mar 07

Incyte announces European Commission approval of Zynyz

TIPRANKS
·
Mar 07